Ultragenyx Pharmaceutical
RARE
300 hedge funds and large institutions have $4.82B invested in Ultragenyx Pharmaceutical in 2024 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 112 increasing their positions, 92 reducing their positions, and 29 closing their positions.
97% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 29
33% more capital invested
Capital invested by funds: $3.63B → $4.82B (+$1.2B)
22% more repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 92
18% more call options, than puts
Call options by funds: $28.2M | Put options by funds: $23.9M
9% more funds holding
Funds holding: 274 → 300 (+26)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3.13% less ownership
Funds ownership: 97.4% → 94.27% (-3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$56M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$48.3M |
| 3 |
Alkeon Capital Management
New York
|
+$39.2M |
| 4 |
Two Sigma Advisers
New York
|
+$27.8M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$20.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$65.8M |
| 2 |
Millennium Management
New York
|
-$58.1M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$53.5M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$46.4M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$27.3M |
RARE Hedge Fund Activity: Q3 2024 in Review
300 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2024, worth a combined $4.82B — up 33% from $3.63B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new RARE positions and 29 closed out — a net gain of 28 holders — while 112 added to existing stakes and 92 trimmed.
The largest buyer was Alyeska Investment Group, adding an estimated $56M. The largest seller was RTW Investments, cutting an estimated $65.8M.
- 300 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2024, up from 274 in Q2 2024.
- Funds reported $4.82B of Ultragenyx Pharmaceutical stock for Q3 2024, up 33% quarter-over-quarter.
- 57 funds opened new Ultragenyx Pharmaceutical positions in Q3 2024 and 29 closed out, a net change of +28 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2024 was Alyeska Investment Group, an estimated $56M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2024 was RTW Investments, an estimated $65.8M sold.
Based on aggregated 13F filings for Q3 2024.